Zyme Communications' Monthly Newsletter

It's been a busy month at Zyme, with lots of exciting biotech industry updates, our office move, and some of the UK's biggest life science conferences including OBN's BioTrinity and LSX World Congress. Find out more in our latest newsletter!

Earlier this month, Zyme moved into our new brand new office space in Waterbeach, Cambridge. The new, bigger facilities offer a workspace we can all use and enjoy, with dedicated spaces for meetings and team lunches.

Now we're settled in, we'd love to invite our connections from across the life science sector to visit our new workspace - drop us a message or pop by for a coffee!

?? A round-up of the latest news from across the life science industry:

• Bio-Rad Laboratories launches first ultrasensitive multiplexed digital PCR assay for breast cancer mutation detection, and announced collaborations with Allegheny Health Network Cancer Institute and Oncocyte
• Preci and BioPredic International partner to increase access to culture-stable suspended pooled hepatocytes with extended longevity from multiple donors
• Metrion Biosciences enhances its High Throughput Screening services with access to Enamine compound libraries, enabling greater flexibility and efficiency in screening and target identification
• Sphere Fluidics appoints Dale Levitzke as Chief Executive Officer and Ed Rayner as Non-Executive Director to progress the Company's continued expansion strategy
• Neurolentech signs technology access partnership with Kaerus Bioscience to advance neurodevelopmental disorder research, leveraging Neurolentech's proprietary cell models and assays for functional screens
• Calluna Pharma appoints Margrethe S?rgaard as Senior Vice President of Clinical Operations and Pharmacovigilance to oversee strategic development of the Company's clinical programs in line with regulatory guidelines and safety requirements
• CN Bio raises $21 million USD in first close of Series B investment round to accelerate the Company's expanding product portfolio and to scale the business to support commercial expansion across key global markets
• Owlstone Medical secures $6.5 Million funding from the Bill and Melinda Gates Foundation to support development of breath-based diagnostics and identify breath biomarkers for tuberculosis and HIV
• Asimov achieves 10x improvement in lentiviral production, and launches its new stable cell line development service. The LV Edge Producer System enables scalable, reproducible, and low-cost production of lentivirus.
• PlaqueTec closes $8 million equity financing to support its ongoing BIOPATTERN trial, designed to improve understanding of CAD pathobiology and to build BIOCARTA?, its biomarker discovery tool

?? A few of our top reads from this month:

Our team have been out and about at plenty of events this month...

? We attended the CONEXEN Networking event, hosted by KISS Communications, where we enjoyed a panel discussion on the growing role of AI in healthcare

? We caught up with colleagues from across the life science investor community at OBN's BioTrinity Investor Networking Drinks

? Our team had a fantastic time at OBN's BioTrinity 2024! Held at Convene, Houndsditch, the conference was attended by a record number of delegates from across the life science sector, including investors, academics, and industry leaders.

Day one kicked off with a welcome presentation from Stuart Rose, CEO of OBN, and a keynote from Tim Haines, executive partner of Abingworth. Both provided a positive outlook on the life sciences, predicting an increasing shift towards data-oriented milestones in company development.

In the Business Track, we enjoyed an insightful panel discussion on 'What it's really like at the helm of some of the UK's leading R&D SMEs'. Senior executives shared their thoughts on how tech companies have adapted to offer hybrid working opportunities, and how we can encourage more academics into industry. Over in the Science Tracks, company spotlight sessions covered a broad range of therapeutic areas from oncology to infectious diseases and immunology.

During the second day of BioTrinity, there was an overarching theme of considering the 'bigger picture' in the Business Track, with discussions on the macro-environmental factors impacting our sector, and how biotech can build stronger long-term relationships with big pharma.

The final session in the Science Tracks was the 'Platforms for drug discovery and development' session, where executives of companies from across the UK and Europe shared updates on how their innovative platforms are enabling the development of novel therapeutics, including Enhanc3D Genomics' genome-wide 3D sequencing technology, Ubiquigent's DUBTAC-focused platform, and Closed Loop Medicine's combination prescription drugs and software products.

To round off the event, Philip Simister, Head of Science and Entrepreneur Advocate at OBN, led a challenging poster showcase, where presenters had 60 seconds to deliver their innovative research pitches. Representatives from institutions such as the University of Oxford presented on topics including photoredox protein modification, next-generation platelet analysis, and novel therapeutic targets for COPD - a great opportunity for academics and early career professionals to pitch to an audience of experienced life science executives.

? And finally, we joined executives from the biotech, medtech, and healthtech sectors at LSX World Congress, hearing how we can transform the future of medicines and improve patient outcomes globally.

? Where are we going?

• SLAS Europe – 27-29 May, Barcelona, Spain
• OBN's BioSeed Summer - 11 June, Level 39, London
• Cambridge Wide Open Day - 12 June, Cambridge

If you're planning to attend any of these events, and would like to arrange a meeting with us, get in touch.

And that's a wrap on this month's industry round-up! Remember to subscribe to our newsletter and follow us on LinkedIn and X for all the latest updates ??